URO-902 not checked

Urovant Sciences GmbH

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Overactive Bladder With Urge Urinary Incontinence
Main trialPhase 2
“This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.”In the company’s words, NCT04211831 on ClinicalTrials.gov
Other names
hMaxi-K · pVAX/hSlo

Other drugs for Overactive Bladder With Urge Urinary Incontinence

All 3 drugs for Overactive Bladder With Urge Urinary Incontinence

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 18 Nov 2021 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow URO-902

Following is part of Solo: you see every change to URO-902 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in